Modern anti-cancer drugs work via tiny molecular motions
Modern immunotherapeutic anti-cancer drugs support a natural mechanism of the immune system to inhibit the…
Browsing: nivolumab
The Oncology Journal Club Episode 18
Find out why coffee is so good for you and hear the team sing Baby…
Combination immunotherapy benefits subset of patients with advanced prostate cancer
Results from a Phase II trial led by researchers at The University of Texas MD…
IASLC WCLC 2020: CheckMate-743 shows that dual immunotherapy, nivolumab plus ipilimumab improves overall survival for patients with previously untreated mesothelioma
The combination of first-line nivolumab and ipilimumab demonstrated an improvement of overall survival for patients…
FDA approves nivolumab for oesophageal squamous cell carcinoma
The Food and Drug Administration (FDA) approved nivolumab for patients with unresectable advanced, recurrent or…
ASCO 2020: Trial confirms durable and long-term survival benefit for nivolumab plus ipilimumab over chemotherapy in metastatic first-line non-small cell lung cancer patients
Today three-year follow-up results from Part 1 of the Phase 3 CheckMate -227 trial have…
FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma
The Food and Drug Administration (FDA) granted accelerated approval to the combination of nivolumab and…
ASCO GU 2020: Nivolumab plus ipilimumab benefit for advanced kidney cancer
Updated results have been released from the Phase 3 CheckMate -214 study evaluating the combination…
Electronic nose can sniff out which lung cancer patients will respond to immunotherapy
An electronic nose that detects chemicals in the breath of lung cancer patients can identify…
Nivolumab combined with ipilimumab safe as first-line therapy for lung cancer patients
Combining the PD-1 immune check point inhibitor nivolumab with the monoclonal antibody ipilimumab showed a…